Role of Vinca Minor in Heavy bleeding

Efficacy of Vinca minor in Heavy Menstrual bleeding due to Uterine fibroids: a Pilot study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042835

Enrollment

Registered

2022-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system Health Condition 2: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Intervention1: Vinca minor: Vinca minor Mother tincture in customized doses of 10-15 drops, thrice daily or twice daily (as per the need of the case) for a week will be administered for every case.

Eligibility

Inclusion criteria

Inclusion criteria: i)Patients suffering from heavy menstrual bleeding due to uterine fibroid (PBAC score = 100 points indicate heavy menstrual bleeding.) with symptoms of Vinca minor (ICD 10: D25.9, N92.0) [17, 18] ii)Age: 18 - 45 years. iii)Uterine fibroid detected on sonography iv) Patients taking Oral Contraceptive Pills will be considered for the study after giving a wash-out period of 1 month. v)Patients giving written consent to participate in the study. vi)Literate patients, who can read and write in Hindi and/or English

Exclusion criteria

Exclusion criteria: 1.Patients who are too sick for consultation. 2. Unwilling to take part and not giving consent to join the study. 3. Unable to read patient information sheet. 4. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life- threatening illness affecting quality of life or any organ failure. 5.Patients suffering from uro-genital polyp, uterine fibroid causing hydronephrosis, fibroid with solid ovarian mass, calcified fibroid. 6. Blood haemoglobin level 7. Patients desiring immediate surgical management for uterine fibroid. 8. Pregnancy and lactation. 9. Substance abuse and/or dependence. 10. Self-reported immune-compromised state. 11. Undergoing homoeopathic treatment for any chronic disease within last 6 months.

Design outcomes

Primary

Measure	Time frame
Higham Pictorial blood loss assessmentTimepoint: Baseline, 1st month, 2nd month, 3rd month	—

Secondary

Measure	Time frame
To compare the Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QOL) after 3 months of interventionTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Lipipushpa Debata

Central Council for Research in Homoeopathy

drlipi08@gmail.com07755014040

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026